After Johnson & Johnson's Break-Up News, 3 Trades To Leverage Recent Stock Dip

 | Nov 22, 2021 08:34

  • Dow-30 member Johnson & Johnson is up 3.4% so far in 2021, but down about 9.2% in the past three months.
  • JNJ recently announced it will spin off the consumer health division
  • Despite potential further volatility in the stock, long-term investors could consider buying Johnson & Johnson shares now
  • On Nov. 12, healthcare giant Johnson & Johnson (NYSE:JNJ), a member of the 30-component, mega cap Dow Jones index, announced that it planned to spin off its consumer health division. That segment is known for numerous high-profile brands such as Aveeno, JNJ Baby Powder, Band-Aid, Listerine and Neutrogena. Management expects the separation to finalize within two years.

    So far, the reaction by investors to the group’s upcoming pharma-driven future has been subdued, and Johnson & Johnson shares have lost about 3% in the past week. Meanwhile, JNJ stock is up close to 3.5% in 2021. By comparison, the Dow Jones US Pharmaceuticals index has returned 20.5% year-to-date.